• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Otonomy Inc.

    12/27/22 5:11:00 PM ET
    $OTIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OTIC alert in real time by email
    SC 13D 1 sc13d00322otic_12272022.htm THE SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. )1

    Otonomy, Inc.

    (Name of Issuer)

    Common stock, par value $0.001 per share

    (Title of Class of Securities)

    68906L105

    (CUSIP Number)

    NEEL PATEL

    elk capital markets uk ltd.

    Flat 6 Radford Court

    814 Old Kent Road

    London, United Kingdom SE15 1AJ

    (937) 475-0380

     

    ANDREW M. FREEDMAN, ESQ.

    OLSHAN FROME WOLOSKY LLP

    1325 Avenue of the Americas

    New York, New York 10019

    (212) 451-2300

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    December 13, 2022

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 68906L105

      1   NAME OF REPORTING PERSON  
             
            Elk Capital Markets UK LTD  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            UNITED KINGDOM  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         4,751,629  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              4,751,629  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            4,751,629  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            8.3%  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    2

    CUSIP No. 68906L105

    The following constitutes the Schedule 13D filed by the undersigned (the “Schedule 13D”).

    Item 1.Security and Issuer.

    This statement relates to the Common stock, par value $0.001 per share (the “Shares”), of Otonomy, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 4796 Executive Drive, San Diego, California 92121.

    Item 2.Identity and Background.

    (a)       This statement is filed by Elk Capital Markets UK LTD., a private limited company (“Elk Capital” or the “Reporting Person”), with respect to the Shares directly and beneficially owned by it.

    (b)       The address of the principal office of the Reporting Person is Flat 6 Radford Court, 814 Old Kent Road, London, United Kingdom SE15 1AJ.

    (c)       The principal business of Elk Capital is investing in securities.

    (d)       The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e)       The Reporting Person has not, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f)       Elk Capital is organized under the laws of the United Kingdom.

    Item 3.Source and Amount of Funds or Other Consideration.

    The Shares purchased by Elk Capital were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 4,751,629 Shares beneficially owned by Elk Capital is approximately $487,517, excluding brokerage commissions.

    Item 4.Purpose of Transaction.

    The Reporting Person purchased the Shares based on the Reporting Person’s belief that the Shares, when purchased, represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Person, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Person may endeavor to increase or decrease its position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Person may deem advisable. The Reporting Person intends to engage in communications with the Issuer’s Board of Directors (the “Board”) and management team regarding opportunities to maximize stockholder value.

    3

    CUSIP No. 68906L105

    The Reporting Person does not have any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. Depending on various factors including, without limitation, the Issuer’s financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Person may in the future take such actions with respect to its investment in the Issuer as it may deem appropriate including, without limitation, engaging in communications with management and the Board of the Issuer, engaging in discussions with stockholders of the Issuer and others about the Issuer and the Reporting Person’s investment, making proposals to the Issuer concerning changes to the capital allocation strategy, capitalization, ownership structure, Board structure (including Board composition) or operations of the Issuer, purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, or changing its intention with respect to any and all matters referred to in Item 4.

    Item 5.Interest in Securities of the Issuer.

    The aggregate percentage of Shares reported owned by the Reporting Person is based upon 57,153,490 Shares outstanding, as of November 4, 2022, which is the total number of Shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2022.

    (a)As of the date hereof, Elk Capital beneficially owned directly 4,751,629 Shares.

    Percentage: Approximately 8.3%

    (b)1. Sole power to vote or direct vote: 4,751,629
    2. Shared power to vote or direct vote: 0
    3. Sole power to dispose or direct the disposition: 4,751,629
    4. Shared power to dispose or direct the disposition: 0

     

    (c)The transactions in the Shares by Elk Capital during the past sixty days are set forth in Schedule A and are incorporated herein by reference.
    (d)No person other than the Reporting Person is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.
    (e)Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Other than as described herein, there are no contracts, arrangements, understandings or relationships between the Reporting Person, or between the Reporting Person and any other person, with respect to the securities of the Issuer.

    Item 7.Material to be Filed as Exhibits.

    Not applicable.

    4

    CUSIP No. 68906L105

    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: December 27, 2022

     

      ELK CAPITAL MARKETS UK LTD
       
      By:

    /s/ Neel Patel

        Name: Neel Patel
        Title: Director

     

    5

    CUSIP No. 68906L105

     

    SCHEDULE A

    Transactions in the Securities of the Issuer During the Past Sixty (60) Days

    Nature of the Transaction

    Amount of Securities

    Purchased/(Sold)

    Price ($)

    Date of

    Purchase/Sale

     

    ELK CAPITAL MARKETS UK LTD

     

    Purchase of Common Stock 5,000 0.0989 10/28/2022
    Purchase of Common Stock 45,100 0.0998 11/01/2022
    Sale of Common Stock (100) 0.1000 11/01/2022
    Purchase of Common Stock 221,011 0.0873 11/07/2022
    Purchase of Common Stock 300,000 0.0881 11/08/2022
    Purchase of Common Stock 580,255 0.0835 11/09/2022
    Purchase of Common Stock 73,897 0.1032 11/10/2022
    Purchase of Common Stock 1,000,000 0.0973 11/11/2022
    Purchase of Common Stock 196,314 0.1227 12/07/2022
    Purchase of Common Stock 2,311 0.1261 12/08/2022
    Purchase of Common Stock 324,139 0.1289 12/12/2022
    Purchase of Common Stock 303,702 0.1227 12/13/2022
    Purchase of Common Stock 700,000 0.1190 12/15/2022
    Purchase of Common Stock 1,000,000 0.0967 12/20/2022

      

    Get the next $OTIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OTIC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright reiterated coverage on Otonomy with a new price target

      HC Wainwright reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously

      3/1/21 8:38:28 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Otonomy with a new price target

      HC Wainwright & Co. reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously

      2/23/21 6:53:19 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler reiterated coverage on Otonomy with a new price target

      Piper Sandler reiterated coverage of Otonomy with a rating of and set a new price target of $5.00 from $10.00 previously

      2/22/21 3:01:01 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Otonomy Announces Change in Stock Exchange Listing

      SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company's shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022. Following such suspension, the company's shares will be traded on the OTC Pink Market. As previously reported, on November 14, 2022, Otonomy received a notice from Nasdaq indicating that the Listing Qualifications Staff (the Staff) had determined to delist the company's securities unless the company timely requested a hearing before the Nasdaq Hearings Panel (the Pan

      12/22/22 7:53:14 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy Provides Corporate Update

      SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that the company's board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution ("Plan of Dissolution") that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including the proceeds from the sale of any pipeline assets. To reduce cost, Otonomy has implemented a reduction in workforce. These updates are discussed below. Evaluation of Strategic Options As previously reported, Otonomy initiated an evaluation of strategic options to realize value from its pipeline. The

      12/19/22 4:53:38 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities. Otonomy Program and Corporate Activity Updates In August 2022, Otonomy announced that OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints in a Phase 2 clinical trial in tinnitus patients. Based on these results, Otonomy discontinued development of OTO-313 and implemented other measures to extend its cash runway. Th

      11/10/22 4:05:00 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

      SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

      2/14/23 4:06:58 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

      SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

      2/13/23 8:49:22 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Otonomy Inc. (Amendment)

      SC 13G/A - OTONOMY, INC. (0001493566) (Subject)

      2/10/23 4:29:37 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Financials

    Live finance-specific insights

    See more
    • Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

      Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment completed for higher dose evaluation with top-line results expected in fourth quarter of 2022OTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biop

      7/25/22 4:05:00 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

      SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022.  A live webcast of the call will be available online in the investor relations section of Otonomy's website at www.otonomy.com and will be archived there for 30 days. To access the live call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minu

      7/18/22 7:30:00 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update

      Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected in August 2022; clinical safety evaluation of higher and bilateral dosing ongoingOTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts and into second half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) --  Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today repor

      5/9/22 4:04:00 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    SEC Filings

    See more
    • SEC Form 15-12G filed by Otonomy Inc.

      15-12G - OTONOMY, INC. (0001493566) (Filer)

      4/4/23 3:40:49 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Otonomy Inc.

      EFFECT - OTONOMY, INC. (0001493566) (Filer)

      4/3/23 12:15:10 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Otonomy Inc.

      EFFECT - OTONOMY, INC. (0001493566) (Filer)

      4/3/23 12:15:09 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Leadership Updates

    Live Leadership Updates

    See more
    • Otonomy Appoints Jill Broadfoot to Board of Directors

      SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appointment of Jill Broadfoot to its board of directors. "Jill is an excellent addition to the board with strong strategic, operational and financial expertise within the biopharmaceutical sector," said David A. Weber, Ph.D., president and CEO of Otonomy. "We are excited to welcome her as we continue our growth trajectory and make progress to achieving our clinical milestones." Since 2018, Ms. Broadfoot has served as chief financial officer (CFO) of aTyr Pharma, Inc., a biotherapeutics company. P

      8/19/21 7:30:00 AM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OTIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Hogan H Michael Iii

      3 - OTONOMY, INC. (0001493566) (Issuer)

      2/24/23 4:53:45 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Weber David Allen covered exercise/tax liability with 91,636 shares, decreasing direct ownership by 24% to 285,863 units (withholding obligation)

      4 - OTONOMY, INC. (0001493566) (Issuer)

      12/30/22 4:31:39 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Cayer Paul E covered exercise/tax liability with 40,054 shares, decreasing direct ownership by 18% to 183,733 units (withholding obligation)

      4 - OTONOMY, INC. (0001493566) (Issuer)

      12/30/22 4:30:19 PM ET
      $OTIC
      Biotechnology: Pharmaceutical Preparations
      Health Care